What a Microbiome Test Really Shows — and What It Doesn't: The Lancet Consensus and 3P Medicine in Practice
The last decade has brought a genuine revolution in our understanding of human biology. Thanks to next-generation sequencing (NGS), science has finally recognized the human body as a complex symbiotic 'superorganism' whose functioning is inseparable from the trillions of microorganisms inhabiting our mucous membranes and skin. Today the gut microbiome is regarded as a full-fledged metabolic and immune organ — responsible for vitamin synthesis, pathogen defense, inflammation control, nervous system function and cellular youth.
Against this scientific boom, the HealthTech and personalized-medicine market has been flooded with commercial microbiome test offers. But alongside the testing hype came myths, speculation and oversimplified interpretations. Buyers are often promised that a single stool test will directly diagnose every disease, find the 'guilty' bacterium and deliver a magic pill for all problems.
To stop the chaotic interpretation of omics data and draw clear lines around clinical utility, leading international medical societies and journals, including The Lancet, have published a series of consensus papers on using microbiome analysis in practical medicine.
In this article we break down the international scientific consensus in detail: we draw a clear line between what a modern microbiome DNA test can really show and which expectations are illusions, and we look at how Ukraine-born biotech solutions from Ediens transform complex genetic data into evidence-based personalized therapy.
1. What a Microbiome Test Does NOT Show: Debunking Common Myths
The international scientific consensus is clear: microbiome analysis is an extremely powerful tool of preventive and personalized medicine — but only when its biological nature is properly understood. To avoid disappointment, the key misconceptions must be debunked.
Myth 1: 'A microbiome test on its own diagnoses a specific disease'
Reality: Microbiome analysis is not a nosological diagnostic test in the classical sense. On its own, without the clinical picture, it cannot diagnose ulcerative colitis, Crohn's disease, diabetes or autoimmune pathologies.
The microbiome reveals predispositions, risks and dysbiotic shift profiles that may accompany or trigger these diseases. But the diagnosis is always made by a physician based on instrumental, laboratory and clinical data combined.
Myth 2: 'There is one perfect “reference” microbiome everyone should aim for'
Reality: There is no universal 'golden formula' of a healthy microbiome that fits every person on the planet. The microbiome is as unique as fingerprints or the pattern of the iris.
Bacterial composition depends on host genetics, birth type, childhood nutrition, geography, ethnicity and even climate. The main health criterion is not copying someone else's bacterial list, but the metabolic functionality and high biodiversity of your own ecosystem.
Myth 3: 'A test result is a static verdict for life'
Reality: Unlike human DNA, which stays unchanged for life, the microbiome's DNA profile is dynamic and plastic. It responds to diet changes, stress levels, antibiotics, sleep quality and physical activity.
A one-off test therefore captures the current state of the ecosystem, and its greatest value unfolds in tracking dynamics — measuring how nutritional correction changes your microbial profile over 30–90 days.
Myth 4: 'Raw tables of bacterial lists have healing value by themselves'
Reality: Receiving a list of hundreds of Latin bacterial names with percentage shares gives the patient zero practical benefit. Without algorithmic processing, functional-pathway assessment and correlation with blood biochemistry, raw sequencing data remains mere 'information noise'.
2. What Molecular Genetic Microbiome Analysis REALLY Shows
If you stop looking for magic diagnoses in the test, NGS-based microbiome analysis opens up a colossal body of high-precision information about the fundamental mechanisms of our health to scientists and practicing physicians.
A. Biodiversity level and ecosystem resilience
The test calculates fundamental ecological indices:
Alpha-diversity index (Shannon index): shows the richness and species diversity of bacterial communities. The higher this index, the more resilient the gut ecosystem is to external shocks — infections, stress, antibiotics or diet changes.
Evenness index (Pielou index): assesses whether one or two bacterial species dominate all others, suppressing overall metabolism.
B. Ratios of major bacterial phyla
Molecular analysis determines the proportions of the main bacterial kingdoms — Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia:
A shift in the Firmicutes/Bacteroidetes ratio toward Firmicutes dominance clearly points to an increased ability of the microbiome to extract extra calories from food — directly linked to risks of obesity, metabolic syndrome and insulin resistance.
An abnormal rise in Proteobacteria share is a universal biomarker of inflammation, hidden dysbiosis and destabilization of the gut barrier.
C. Presence and titers of key protective bacteria (key drivers)
The analysis shows the exact levels of unique beneficial microorganisms performing critical physiological functions:
Akkermansia muciniphila: the chief guardian of the gut barrier. This bacterium lives in the mucus layer, renews mucin, controls the density of intercellular contacts (zonulin) and protects against endotoxins entering the blood.
Faecalibacterium prausnitzii: one of the main producers of butyrate — a short-chain fatty acid that feeds gut epithelial cells, suppresses inflammation and protects against colon cancer risks.
Bifidobacterium spp. and Lactobacillus spp.: suppress pathogens, normalize pH, synthesize B vitamins and support oral-gut immunity.
D. Metabolic potential and systemic risk assessment
Modern analysis assesses not only 'who lives in the gut' but 'what they do':
Short-chain fatty acid (SCFA) synthesis capacity: the potential to produce butyrate, acetate and propionate.
Metabolic endotoxemia risk: detecting excess Gram-negative bacteria producing lipopolysaccharides (LPS) that cause chronic low-grade systemic inflammation.
TMAO accumulation predisposition: assessing bacterial groups that metabolize choline and carnitine into trimethylamine, raising atherosclerosis risks.
3. From Raw Data to Clinical Benefit: Bridging the Gap Between Test and Action
The key takeaway of the Lancet consensus is this: the value of microbiome analysis is determined not by the mere fact of taking the test, but by the accuracy and evidence base of the algorithm that turns genetic data into practical recommendations.
For the test to genuinely work for your health, three elements must come together:
High-precision diagnostics (NGS sequencing): identifying bacterial DNA at genus and species level.
Algorithmic bioinformatics processing: interpreting data with validated scientific knowledge bases.
Personalized instruments of influence: designing an individual nutrition plan (where food works as a prebiotic) and prescribing targeted clinical pharmabiotics.
4. The Ediens Solution: Microbiome DNA Research and the Biocode4U System
The Ukrainian MedTech/BioTech company Ediens, founded under the scientific leadership of Doctor of Biological Sciences, Professor Nadiya Volodymyrivna Boyko, builds on more than 35 years of fundamental research in molecular microbiology, immunology and metabolomics.
Ediens developments fully align with the global scientific consensus, offering not just 'analysis for analysis' sake' but a closed loop of personalized 3P medicine.
Step 1. High-precision microbiome research (NGS sequencing)
You provide a biological sample for full molecular genetic analysis. The Ediens laboratory uses 16S rRNA sequencing on modern platform facilities. This decodes the DNA of your entire gut bacterial spectrum, determining biodiversity indices, phyla ratios, protective strain levels (Akkermansia, Faecalibacterium, Bifidobacterium) and conditionally pathogenic concentrations.
Step 2. Bioinformatic processing by the EdiensUniCode (BioQuantum) algorithm
The resulting genetic passport is uploaded to a proprietary cloud platform. The EdiensUniCode (BioQuantum) algorithm matches your microbiota shift deviations against an expanded in-house database of plant-vs-bacteria bioactive interactions.
The system builds a Microbiome Nutrition Plan (within the Biocode4U system) — a personalized diet based on traditional local and fermented foods. Its plant ingredients are calculated as high-precision prebiotics for exactly those beneficial strains your body lacks.
Step 3. Targeted Ediens pharmabiotics
To rapidly suppress pathogens and heal the gut barrier, a course of new-generation proprietary pharmabiotics is prescribed based on test results:
'My Second Brain. Gut Microbiome': the flagship sachet pharmabiotic with a high working concentration of live clinically validated strains (Lactobacillus bulgaricus, Lactobacillus rhamnosus S25). It actively suppresses putrefactive processes, relieves bloating, restores mucosal tight contacts and normalizes motility.
'Metabolic Antistress': a formula based on the patented Lactobacillus plantarum IMB B-7414 strain, acting via the gut–brain axis — lowering cortisol, restoring deep sleep and relieving stress-induced GI spasms.
Step 4. Creating an individual commensal microbiota bank
After completing the recovery course, Ediens offers a unique service — cryopreservation of your own isolated beneficial bacteria in a personal bank. This biological insurance lets you instantly restore your unique microbiome in the future after antibiotics or infections.
Conclusions
A microbiome test is not a magic bullet for isolated diagnosis hunting, but a high-precision map of your inner metabolic and immune health. As the Lancet consensus stresses, what matters is not merely having a list of bacteria, but the correct, evidence-based interpretation of that data.
Thanks to molecular genetic microbiome research and the Biocode4U digital platform (Microbiome Nutrition Plan) from Ediens, you get a clear, scientifically calculated recovery algorithm. It tames hidden inflammation, heals the gut barrier and returns high energy, lightness and longevity to your body!
Quick questions and answers (Q&A)
1. Can a microbiome test diagnose a specific disease on its own?
No — the international scientific consensus stresses that microbiome analysis is not a standalone diagnostic test for establishing a specific nosology. It shows dysbiotic shifts, biodiversity, metabolic risks and inflammation levels accompanying disease. The final diagnosis is always made by a physician based on combined clinical and laboratory data.
2. How does NGS molecular microbiome analysis differ from a regular dysbiosis culture?
A regular culture detects only a tiny fraction (about 1–5%) of aerobic bacteria able to grow in a Petri dish in the presence of oxygen. NGS molecular genetic analysis (16S rRNA sequencing) decodes the DNA of absolutely all microorganisms in the sample, including anaerobic bacteria that make up over 95% of the gut ecosystem.
3. What is the Shannon index in microbiome test results and why does it matter?
The Shannon index is a fundamental ecological measure of alpha diversity. It reflects the richness and species diversity of bacterial communities in your gut. The higher the Shannon index, the more resilient your digestive and immune systems are to stress, antibiotics, infections and environmental factors.
4. How does the Ediens Biocode4U platform turn analysis results into practical benefit?
The Biocode4U platform processes DNA-sequencing data with the proprietary EdiensUniCode (BioQuantum) IT algorithm. It matches your bacterial deficits against a database of plant-substance vs bacteria interactions, creating a personal Microbiome Nutrition Plan. This precisely calculated menu of local and fermented foods, combined with targeted pharmabiotics (e.g. 'My Second Brain'), restores your deficient bacteria and heals the gut barrier.
Comments